|Chemical and physical data|
|Molar mass||353.44 g/mol g·mol−1|
|3D model (JSmol)|
|(what is this?)|
Intepirdine (INN; developmental codes SB-742457, RVT-101) is a selective 5-HT6 receptor antagonist with potential cognition, memory, and learning-enhancing effects. It was under development by GlaxoSmithKline for the treatment of Alzheimer’s disease and demonstrated some preliminary efficacy in phase II clinical trials. GSK chose not to continue development and sold the rights to Axovant Sciences for $5 million in December 2014.
Results of a phase III clinical trial for the treatment of Alzheimer’s disease were reported in September 2017. The trial showed no improvement over control group and Axovant lost 70% of its value upon the announcement of the trial results.
- “Intepirdine – Axovant Sciences / GlaxoSmithKline”. AdisInsight. Retrieved 9 January 2018.
- Upton N, Chuang TT, Hunter AJ, Virley DJ (July 2008). “5-HT6 receptor antagonists as novel cognitive enhancing agents for Alzheimer’s disease”. Neurotherapeutics. 5 (3): 458–69. doi:10.1016/j.nurt.2008.05.008. PMID 18625457.
- Rossé G, Schaffhauser H (February 2010). “5-HT(6) Receptor Antagonists as Potential Therapeutics for Cognitive Impairment”. Current Topics in Medicinal Chemistry. 10 (2): 207–21. doi:10.2174/156802610790411036. PMID 20166958.
- Lowe, Derek (12 May 2015). “An Alzheimer’s IPO, Because Why Not”. In the Pipeline.
- Fiore, Kristina (27 September 2016). “NeuroBreak: Alzheimer’s Drug Bombs; Elephant Tranquilizer ODs”. MedPage Today.
- Garde, Damian (26 September 2017). “Another Alzheimer’s failure: Axovant’s drug flops in late-stage trial”. STAT.
- Taylor, Phil (Jan 8, 2018). “Axovant slumps as it dumps lead drug intepirdine”. Fierce Biotech.